Standard BioTools to Release Q4 and Full Year 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy LAB?
Source: Newsfilter
- Earnings Announcement: Standard BioTools Inc. will publish its fourth quarter and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to provide investors with the latest insights into the company's operational performance.
- Technological Edge: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses pressing needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, highlighting its significant role in the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, and biotechnology laboratories worldwide, aiming to provide reliable and repeatable insights into health and disease, further solidifying its market leadership.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LAB
Wall Street analysts forecast LAB stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 1.000
Low
1.35
Averages
1.35
High
1.35
Current: 1.000
Low
1.35
Averages
1.35
High
1.35
About LAB
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LAB Rises More Than 2.2x in Just One Day, Leading to Over $6 Million in Long Liquidations Overall
Current Trading Status: LA B is currently trading at $2.19, having surged to $2.3 with a 24-hour gain of 221%.
Total Liquidity Value: The total value of liquidations in LA B's contract trading across all platforms reached $6.39 million in the past 24 hours.
Long vs. Short Liquidations: Long liquidations amounted to $1.07 million, while short liquidations totaled $5.31 million.
Market Activity: The significant trading activity indicates a volatile market environment for LA B, reflecting substantial investor interest.
See More
Standard BioTools Inc. to Release Q1 2026 Financial Results on May 5
- Earnings Announcement: Standard BioTools Inc. has announced that it will publish its Q1 2026 financial results on May 5, 2026, after the U.S. market close, reflecting the company's ongoing commitment to transparency and investor communication.
- Technological Foundation: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses critical needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, underscoring its significant position and influence within the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, biotechnology, and clinical laboratories worldwide, emphasizing its broad impact in advancing biomedical research and innovation.
See More
Standard BioTools to Announce Q4 Earnings on February 24
- Earnings Announcement Date: Standard BioTools is set to release its Q4 earnings on February 24 after market close, with a consensus EPS estimate of -$0.03, reflecting a 66.7% year-over-year increase, while revenue is expected to decline by 60.4% to $18.5 million, indicating significant challenges ahead.
- Historical Performance Review: Over the past year, Standard BioTools has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, suggesting stability in revenue management but a need for improvement in profitability.
- 2025 Outlook: The company reported preliminary revenue of $85 million from continuing operations for 2025, exceeding estimates, although the overall outlook remains murky, which could impact investor confidence.
- Market Reaction Expectations: Given the significant revenue decline indicated in the upcoming earnings report, market reactions to Standard BioTools may lean negative, prompting investors to closely monitor how the company addresses its current financial challenges.
See More
Standard BioTools to Release Q4 and Full Year 2025 Financial Results
- Earnings Announcement: Standard BioTools Inc. will publish its fourth quarter and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to provide investors with the latest insights into the company's operational performance.
- Technological Edge: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses pressing needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, highlighting its significant role in the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, and biotechnology laboratories worldwide, aiming to provide reliable and repeatable insights into health and disease, further solidifying its market leadership.
See More
Standard BioTools Completes Sale of SomaLogic to Illumina
- Significant Transaction Value: Standard BioTools completed the sale of SomaLogic to Illumina for $350 million in cash, with an additional potential earnout of up to $75 million, bringing the total transaction value to $425 million, marking a major milestone in the company's strategic transformation.
- Strong Cash Reserves: Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, providing robust financial resources for future M&A activities, thereby accelerating growth in a competitive industry landscape.
- Profitability Outlook: The company is on track to achieve positive adjusted EBITDA by 2026, reflecting improved operational efficiency and indicating a strong recovery capability in market competition, which enhances investor confidence.
- Long-Term Revenue Potential: Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based products for the next ten years, creating a stable revenue stream that supports ongoing innovation and market expansion strategies.
See More
STANDARD BIOTOOLS FINALIZES SALE OF SOMALOGIC TO ILLUMINA
- Sale Announcement: Standard Biotools has completed the sale of Somalogic to Illumina.
- Strategic Move: This acquisition is expected to enhance Illumina's capabilities in the field of genomics and proteomics.
See More
LAB Rises More Than 2.2x in Just One Day, Leading to Over $6 Million in Long Liquidations Overall
Current Trading Status: LA B is currently trading at $2.19, having surged to $2.3 with a 24-hour gain of 221%.
Total Liquidity Value: The total value of liquidations in LA B's contract trading across all platforms reached $6.39 million in the past 24 hours.
Long vs. Short Liquidations: Long liquidations amounted to $1.07 million, while short liquidations totaled $5.31 million.
Market Activity: The significant trading activity indicates a volatile market environment for LA B, reflecting substantial investor interest.
See More
Standard BioTools Inc. to Release Q1 2026 Financial Results on May 5
- Earnings Announcement: Standard BioTools Inc. has announced that it will publish its Q1 2026 financial results on May 5, 2026, after the U.S. market close, reflecting the company's ongoing commitment to transparency and investor communication.
- Technological Foundation: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses critical needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, underscoring its significant position and influence within the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, biotechnology, and clinical laboratories worldwide, emphasizing its broad impact in advancing biomedical research and innovation.
See More
Standard BioTools to Announce Q4 Earnings on February 24
- Earnings Announcement Date: Standard BioTools is set to release its Q4 earnings on February 24 after market close, with a consensus EPS estimate of -$0.03, reflecting a 66.7% year-over-year increase, while revenue is expected to decline by 60.4% to $18.5 million, indicating significant challenges ahead.
- Historical Performance Review: Over the past year, Standard BioTools has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, suggesting stability in revenue management but a need for improvement in profitability.
- 2025 Outlook: The company reported preliminary revenue of $85 million from continuing operations for 2025, exceeding estimates, although the overall outlook remains murky, which could impact investor confidence.
- Market Reaction Expectations: Given the significant revenue decline indicated in the upcoming earnings report, market reactions to Standard BioTools may lean negative, prompting investors to closely monitor how the company addresses its current financial challenges.
See More
Standard BioTools to Release Q4 and Full Year 2025 Financial Results
- Earnings Announcement: Standard BioTools Inc. will publish its fourth quarter and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to provide investors with the latest insights into the company's operational performance.
- Technological Edge: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses pressing needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, highlighting its significant role in the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, and biotechnology laboratories worldwide, aiming to provide reliable and repeatable insights into health and disease, further solidifying its market leadership.
See More
Standard BioTools Completes Sale of SomaLogic to Illumina
- Significant Transaction Value: Standard BioTools completed the sale of SomaLogic to Illumina for $350 million in cash, with an additional potential earnout of up to $75 million, bringing the total transaction value to $425 million, marking a major milestone in the company's strategic transformation.
- Strong Cash Reserves: Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, providing robust financial resources for future M&A activities, thereby accelerating growth in a competitive industry landscape.
- Profitability Outlook: The company is on track to achieve positive adjusted EBITDA by 2026, reflecting improved operational efficiency and indicating a strong recovery capability in market competition, which enhances investor confidence.
- Long-Term Revenue Potential: Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based products for the next ten years, creating a stable revenue stream that supports ongoing innovation and market expansion strategies.
See More
STANDARD BIOTOOLS FINALIZES SALE OF SOMALOGIC TO ILLUMINA
- Sale Announcement: Standard Biotools has completed the sale of Somalogic to Illumina.
- Strategic Move: This acquisition is expected to enhance Illumina's capabilities in the field of genomics and proteomics.
See More
